Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

Table 6 Nanocapsule characteristics and information

Shell ligand	Particle size (nm) ^a	Zeta potential (meV) ^b	Morphology ^c	Cargo ^d	Sequence ^e
Tenfibgen	27.7 ± 4.6	−7.4 ± 4.2	Uniform, single capsules	siCDK11	5′-gagcgagcagcagcgugugdTdT-3′
27 kDa	27.7 ± 4.6	−7.4 ± 4.2	Uniform, single capsules	siCDK11	5′-gagcgagcagcagcgugugdTdT-3′
Tenfibgen	20.7 ± 5.2	−1.7 ± 2.4	Uniform, single capsules	siCK2	5′-auacaacccaaacuccacaudTdT-3′
27 kDa	20.7 ± 5.2	−1.7 ± 2.4	Uniform, single capsules	siCK2	5′-auacaacccaaacuccacaudTdT-3′
Tenfibgen	16.2 ± 2.4	−7.8 ± 4.2	Uniform, single capsules	siCON1	5′-uagcgacuaaacacaucaauudTdT-3′
27 kDa	16.2 ± 2.4	−7.8 ± 4.2	Uniform, single capsules	siCON1	5′-uagcgacuaaacacaucaauudTdT-3′

CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; TEM, transmission electron microscopy. ^aMean ± standard deviation of the average elliptical diameter determined from TEM micrographs measuring at least 20 nanocapsules. ^bAverage surface charge measured by dynamic light scattering from two different preparations across a 20 V potential in 1 mM KCl at 2 μg/ml. Data shown as the mean ± standard error of 15 independent measurements. ^cMorphology of all nanocapsules determined by visual atomic force microscopy and TEM observation as uniform, single capsules. ^dTBG-siCDK11, siCK2, and siCON1 encapsulation efficiencies mean of 54.0%, 86.8%, and 69.2%, respectively, observed by Burton analysis relative to unencapsulated siRNA. ^eSense strand sequence.

ISSN: 1465-542X